Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Has Dr. Steve given up? I notice he is now the board moderator, a job which has rotated through the ranks. Where has he been the last month or two?
Enmd 2076 in combo with Kevetrin for treatment of esophageal cancer???
"[Aurora kinases and cancer].
[Article in Japanese]
Kimura M, Okano Y.
SourceDept. of Molecular Pathobiochemistry, Division of Disease Control, Gifu University Graduate School of Medicine, Japan.
Abstract
Aurora kinases are highly conserved in eukaryotes and involved in many processes during cell division. Three Aurora kinases have been identified in humans and designated as Aurora-A, -B, and -C. Aurora A regulates centrosome function during M phase through its interactions with various cell cycle regulators including TACC, chTOG, Ajuba, BRCA1, LATS2, and p53. Aurora-B localizes at the kinetochore from G2 to metaphase, and relocates to the midbody after anaphase. Aurora-B plays roles in spindle dynamics, chromosome condensation, and cytokinesis by interacting with many proteins such as INCENP, Survivin, CENP-A, MgcRacGAP, and intermediate filaments. Overexpression of both Aurora-A and -B proteins is frequently observed in various human cancer tissues, and a common coding region polymorphism in aurora-Aaffects the risk of breast or esophageal cancer. Ectopic overexpression of Aurora-A or -B protein leads to aneuploid cells. The cells overexpressing active Aurora A or wildtype Aurora-B are tumorigenic in nude mice.
http://www.ncbi.nlm.nih.gov/pubmed/15675572
http://www.biomedcentral.com/content/pdf/1471-2121-12-13.pdf"
...an excellent reveiew of the biomarker development process underway in the TNBC trials presented by Jennifer Diamond...
http://www.entremed.com/files/Diamond022113.pdf
Tak Mak and UCLA colleague announce new drug discovery...
http://www.ascopost.com/issues/july-10,-2013/investigational-new-drug-application-filed-for-cfi-400945.aspx
...more...
"AUGUST 7, 2013 · 9:43 AMGate 10 Leads to Year 11 – Field of Dreams
http://getpassioncapital.files.wordpress.com/2013/08/toronto-20130807-00177.jpg
This is Gate 10 at the southwest corner of the Rogers Centre and this is also the entry way for all participants in the Shoppers Drug Mart Weekend to End Women’s Cancers to be held September 7th and 8th. Early Saturday morning all the thousands of walkers and volunteers will make their way through Gate 10 and down to the field of the Rogers Centre for opening ceremonies. The support of the Toronto Blue Jays and the Rogers family has been incredible and we will call the Rogers Centre home Saturday night to sleep over and celebrate. Dr. Tak Mak has huge news on his new drug that has been approved by Health Canada, and Saturday night will be special as we all gather to hear performances by Burton Cummings and Johnny Reid. I’ll be sleeping out on the field in a tent with a couple thousand of my walking buddies. This is going to be the 11th year of the Walk and it will be the best route ever both days. With the Rogers Centre, we will truly be celebrating on a “Field of Dreams”. Here’s the web site because plenty of time to register and donate. Go to www.endcancer.ca."
it not only activates native p53 gene but it has some ability to inactivate mutant p53 during cell cycle regeneration.
It basically has the ability to ameliorate mutant p53 and the phase 1 trial is actively ongoing at Dana Farber and they are probably onto the 5th cohort and have not reached MTD nor has there been any severe adverse reactions.
How about using both Kevetrin and ENMD 2076 in triple negative breast cancer that shows over expression of mutant p53??
Dont want to jump ahead too far,stay tuned.
Cellceutix's Kevetrin to begin P1 trial... said to activate P53...
http://cellceutix.com/kevetrin/
ROCKVILLE, Md., Aug. 14, 2013 - EntreMed, Inc. (ENMD [1]), a
clinical-stage pharmaceutical company developing therapeutics for the
treatment of a variety of cancers, today reported financial results
for the three and six-month periods ended June 30, 2013.
EntreMed reported a net loss for the second quarter of 2013 of ($1.9
million), or ($0.07) per share. This compares with a net loss of
($10.5 million), or ($0.56) per share, for the same period last
year. For the first six months of 2013 the reported net loss was
($3.0 million), or ($0.12) per share as compared to ($13.0 million),
or ($0.86) per share for 2012. The 2012 net loss was primarily
attributed to non-cash interest charges associated with our financing
in 2012 ($9.2 million and $10.0 million for the three and six months
ended June 30, 2012, respectively). Excluding this non-cash
interest, net loss for the second quarter and first six months of 2012
was ($1.3 million), or ($0.07) per share and ($3.0 million) or ($0.19)
per share, respectively.
As of June 30, 2013, EntreMed had cash and cash equivalents of
approximately $17.2 million.
Sara B. Capitelli, EntreMed's Vice President, Finance & Principal
Accounting Officer, commented on the second quarter results, "Our
second quarter 2013 financial results were in line with
expectations. Our research and development expenses for the second
quarter increased compared to the previous year due to costs
associated with the clinical development of ENMD -2076 in the U.S. and
China during 2013. Our general and administrative expenses for the
second quarter of 2013 increased compared to the previous year,
reflecting an increase in non-cash stock based compensation of $0.4
million. We anticipate third and fourth quarter research and
development expenses to increase primarily due to costs related to the
Company's crossover bioavailability and food effect study of
ENMD-2076."
Ken Ren, PhD, EntreMed's Chief Executive Officer, further commented,
"Our finances are stable and reflect our prudent management of
resources. As we continue to deploy our capital in value-building
and efficient ways, we continue to advance the clinical development of
ENMD-2076, expand our capability in China, and will explore
opportunities to enhance value and build our pipeline. We are
optimistic about our company's prospects and look forward to further
execution of our drug development strategy."
Ohlin Frank, a trained chocolate Labrador has been able to detect ovarian by sniffing urine.
That is amazing itself.
Now we need a few trials targeting clear cell ovarian cancer that is not surgically resectable that has not been treated with several first line agents that have failed.
My hunch is that ENMD 2076 will work well We need those trials and it may have to expand to China to recruit enough patients
It would be great to see EntreMed follow thru on performing trials on the clear cell subset of ovarian cancers since it appears that ENMD 2076 worked well as a single agent .
They know this subset of ovarian cancer had an over expression of mutant P53
and this has become a valuable biomarker for directed therapies.
ENMD 2076 is a potent oral KI and may have some interaction in p53 pathway,
mutant to native ratio reversal ?
P53 and P21 bioassays are now available at large centers like Dana Farber and they can follow the P53 pathway by looking for P21 one of the later links in this critical pathway of cellular cytokines responsible for elimination of mutant gene replication during mitosis
Just goes to show that not everything is bad when things go to the dogs!
Dogs can sniff out cancer with 100 per cent accuracy: study
August 11, 2013 23:40 IST
“Washington: Woman's best friend! Researchers have trained dogs to sniff out the signature chemical compound that indicates the presence of ovarian cancer with 100 per cent accuracy.
Ohlin Frank, a trained chocolate Labrador has been able to detect ovarian cancer tissue 100 per cent of the time, researchers said.
Frank and its fellow trainee, McBaine Chamberlain, a spunky springer spaniel, are a part of an interdisciplinary research project at the University of Pennsylvania to help scientists discover a chemical footprint that might lead to earlier diagnostic tests to save human lives.
They are among 15 carefully bred detection dogs learning to sniff out explosives, drugs and missing people.
Researchers are using the keen sense of smell of the dogs to identify the earliest odour of ovarian cancer, a silent killer often diagnosed too late, 'ABCNews.com' reported.
Cancer cells leave a detectable bio-marker, just as asparagus can affect the smell of urine when eaten.
Penn Vet founder and executive director Cynthia M Otto hopes the dogs can be trained to narrow down a specific odour within two years, so scientists can design an inexpensive and less-invasive blood test to catch ovarian cancer while it's still treatable.
"All dogs are really good at sniffing, but part of what gives them a huge advantage over us is the surface area of the olfactory receptors," Otto said.
The dogs have already been introduced to the cancer tissue smell and were taught to sit when they found it.
Otto's work builds on a 2010 Swedish study, which used pet giant schnauzers to detect ovarian cancer. Tissue tests showed sensitivity of 100 per cent and specificity of 95 per cent; blood tests showed sensitivity of 100 per cent and specificity of 98 per cent, the report said.
Dogs with long noses have the largest surface areas of olfactory receptors, said researchers.”
http://www.ndtv.com/article/world/dogs-can-sniff-out-cancer-with-100-per-cent-accuracy-study-404433
Now can they train the dogs to detect who will respond to ENMD 2076? Why not?
Aaron
I don't think they have dropped the ball, but it does appear that they are trying to quantify the data to identify the target group that will be most responsive. The recently announced trial which will examine bioavailabilty and the effect of the ingestion of food, and the soft tissue sarcoma trial now recruiting, as well as the TNBC trial currently underway will add to the developing data base.
http://healthinfoispower.wordpress.com/2013/01/14/enmd-2076-monotherapy-demonstrates-anti-cancer-activity-in-recurrent-platinum-resistant-ovarian-clear-cell-carcinoma/
What ever happened to the subset of ovarian cancer, namely clear cell and it's sensitivity to ENMD 2076?
They seemed to have identified the p53 over expression in this population of ovarian cancer as well as sarcoma.
Why has Entremed dropped the ball ?
Great review, Aaron...
Enmd 2076 and VEGF inhibition
”Notably, Dr. Matulonis also commented on the anti-cancer activity of ENMD-2076 in three ovarian clear cell carcinoma patients as follows:
“ENMD-2076 also showed anti-cancer activities in patients with clear cell carcinoma [CCC], a histological subtype considered as chemo-resistant. Two of three [CCC] patients recruited had longer PFS than the median with one patient in stable disease for over two years. As recent reports suggest VEGF is frequently expressed in clear cell cancers, this subtype might be particularly responsive to therapies that incorporate VEGF inhibition. Further clinical evaluations of ENMD-2076 may therefore be warranted in this patient subset either as a single agent or in combinations.” [emphasis added]”
From
http://healthinfoispower.wordpress.com/2013/01/14/enmd-2076-monotherapy-demonstrates-anti-cancer-activity-in-recurrent-platinum-resistant-ovarian-clear-cell-carcinoma/
“Although bevacizumab is the most studied anti-VEGF agent to date, research with many other potential agents is ongoing. Current investigations are now evaluating small-molecule inhibitors of the tyrosine kinase (TK) associated with the VEGF receptors. Several of these have made it to phase 2 trials with reasonable response rates but need more data prior to their widespread use…”
From
http://www.medscape.org/viewarticle/533941_6
“ENMD-2076 is a novel, orally-active molecule that has been shown to have significant activity against aurora and multiple receptor tyrosine kinases.”
From
http://www.ncbi.nlm.nih.gov/pubmed/20560971
The phase 2 Ovarian Trial continues because patients are still alive !!!
ENMD 2076 is definitely working.
Why do you say it appears to be working?
Enmd 2076 appears to be working
There must be something specific about the biomechanics of how it becomes available in the human blood stream
This could be the oral equivalent of avastin and much better tolerated
Waiting is the hardest part for the results of this new study
The volunteers will be nicely paid
One of the big problems with any drug taken orally is the absorption into the bloodstream without significant breakdown before reaching its target. This runs contrary to the digestive process. The current study will take into consideration the food types ingested, or not ingested to maximize the bioavailability of the drug at its intended target.
Several years ago it was determined that drinking grapefruit juice had a negative effect on the activity of statins. And, you may remember that grapefruit juice, at one time, was the mainstay of the “Weight Watchers” diet. It was believed that the acidic nature of the juice inhibited the digestive process. This theory was based upon the fact that the digestive process is initiated by the ingestion of food that increased the pH in the gut.
Bioavailability is a major problem with 2ME taken orally (Endostatin, as well) and was the basis for its reformulation as Panzem and the use of nano-technology.
While it may appear that the current study is an effort to fine-tune drug delivery, importantly, it is another indication that this current group of scientists is interested in dotting the i’s and crossing the t’s to more fully understand the MOA of the drug and maximizing it's effectiveness in clinical trials.
Thanks for sharing, Rocky
EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
ROCKVILLE, Md., July 29, 2013 - EntreMed, Inc. (ENMD), a
clinical-stage pharmaceutical company developing therapeutics for the
treatment of a variety of cancers, announced today that it has
initiated a crossover bioavailability and food effect study of
ENMD-2076. The study is a single-blind, randomized, single-dose,
crossover study with a food effect arm to investigate the safety and
relative bioavailability of two dosage forms of ENMD-2076 administered
as escalating doses in two cohorts of healthy subjects. The study is
expected to enroll approximately 29 healthy adult volunteers and will
be conducted in Tempe, Arizona by a clinical research organization.
EntreMed anticipates the clinical portion of the study will be
completed by year end, and that pharmacokinetic analysis will be
completed in early 2014.
Ken K. Ren, Ph.D., EntreMed's Chief Executive Officer, commented,
"The primary objective of this study is to compare the bioavailability
and pharmacokinetic profile of two dosage forms of ENMD-2076 and to
assess the effect of food on the bioavailability. This crossover
study will enable the company to satisfy the FDA's requirements on the
formulated product of ENMD-2076 that can be used for our
pivotal/registration clinical trials. This study is another step
towards the advancement of our ENMD-2076 drug development program."
About ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor
with a unique kinase selectivity profile and multiple mechanisms of
action. ENMD-2076 has been shown to inhibit a distinct profile of
angiogenic tyrosine kinase targets in addition to the Aurora A kinase.
Aurora kinases are key regulators of mitosis (cell division), and are
often over-expressed in human cancers. ENMD-2076 also targets the
VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important
roles in the pathology of several cancers. ENMD-2076 has shown
promising activity in Phase 1 clinical trials in solid tumor cancers,
leukemia, multiple myeloma, and is currently completing a Phase 2
trial for ovarian cancer. EntreMed is currently conducting a
dual-institutional Phase 2 study of ENMD-2076 in triple-negative
breast cancer and a Phase 2 study in advanced/metastatic soft tissue
sarcoma. ENMD-2076 has received orphan drug designation from the FDA
for the treatment of ovarian cancer, multiple myeloma and acute
myeloid leukemia.
I don't think so... This is a pre-clinical scientific study a long way from product development which may or may not be an issue. And don't forget the patent for 2ME2 is owned by Children's Hospital, not Enmd... Enmd has a 2ME trademarked product, Panzem, and a use patent for delivery using nanocell technology...
"Patent No. 7,081,477, entitled "Estrogenic Compounds as Anti-Mitotic Agents," contains claims granted by the U.S. Patent Office covering methods of using 2ME2 to treat diseases that are characterized by abnormal cell division (mitosis), including cancer and non-oncology diseases. The claims are independent of mechanism and cover various cancers, tumor metastases, vascular abnormalities, inflammatory and immune disorders, and abnormal angiogenesis that accompanies diseases such as rheumatoid arthritis. The patent also covers multiple formulations for 2ME2. The inventors are Drs. Robert D'Amato and Judah Folkman from Children's Hospital Boston. Children's Hospital has licensed 2ME2 exclusively to EntreMed. "
Generic 2ME2 is available from formulation houses for research use...
TB,
Is this part of an Entremed study. I would think it would be, wouldn't they need enmd permission
To use 2me2 in any study?
Thanks
2-ME in combo with Quercetin in pre-clinical testing in China:
"Quercetin synergizes with 2-methoxyestradiol inhibiting cell growth and inducing apoptosis in human prostate cancer cells.
Wang G, Song L, Wang H, Xing N.
Source
Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, P.R. China.
Abstract
Lack of effective treatment options for castration-resistant prostate cancer reinforces the great need to develop novel drug therapies. Quercetin is a plant-derived ?avonoid that can induce apoptosis in prostate cancer cells. 2-Methoxyestradiol (2-ME) is an endogenous estrogenic metabolite that also has antineoplastic activity. However, these two agents have limited bioavailability. Herein, we explored the antiproliferative and proapoptotic activities of quercetin combined with 2-ME in both androgen-dependent LNCaP and androgen-independent PC-3 human prostate cancer cell lines. Compared to quercetin and 2-ME alone, combining quercetin with 2-ME at appropriate concentrations i) showed synergistic antiproliferative and proapoptotic activities; ii) increased G2/M phase population of cells; iii) decreased the ratio of Bcl-2/Bax significantly. The combination of quercetin and 2-ME is a new clinically relevant treatment regimen which has the potential of enhancing the antitumor effect on prostate cancer and lessening the side effect of either quercetin or 2-ME alone."
Why so quiet at Entremed???
Dr. Ren: “In terms of our outlook for 2013, we remain focused on building a leading oncology enterprise that integrates US and China strategies and resources for cost effective drug development. We intend to achieve the following objectives:
Continue the development of ENMD-2076, including initiating global clinical trials with sites in China under our U.S. FDA IND, and in parallel, pursuing local development in China under SFDA;
Pursue an additional clinical-stage drug candidate to add to our pipeline; Further develop our regulatory and clinical capability in China."
Only two trials are open and recruiting patients. The TNBC Phase 2 trial currently underway was originally scheduled to collect primary data by January 2014. However, this will depend upon successfully enrolling the target of 34 patients.
The recently started trial for soft tissue sarcoma is scheduled to be completed by April 2015... again dependent upon successful completion of enrollment of 25 patients.
It appears that the news most likely to surface in the short term will be administrative... i.e., progress with the China venture and the potential commencement of trials in China...
Phase III info on the P53 biomaker...
http://med.miami.edu/news/phase-iii-trial-shows-biomarkers-predict-p53-gene-therapy-efficacy
...future technology... pretty amazing stuff...
"Fascinating technological advances -
This amazing medical technology, currently being developed in Israel, is a new approach to corrective medicine. It treats most of today’s surgical procedures (tumors, cancers, Parkinson's, stroke, brain disorder, etc.) on an outpatient basis; then sends the patient home immediately afterward, with no recovery time. It is totally noninvasive, eliminating long hospital stays."
<
Yes, a nice announcement to be sure, but again, nothing that makes the cash register
ring. More trials and more hope for good results, but nothing to get the stock going
On a consistent upward path.
7:02AM EntreMed files new drug global clinical trial application for ENMD-2076 with China CFDA to expand clinical trial for advanced/metastatic sarcoma (ENMD) 1.95 : The purpose of the application is to expand the Company's Phase 2 clinical trial in advanced/metastatic sarcoma which currently is being conducted at Princess Margaret Hospital. This submission is the Company's second new drug global clinical trial application with the CFDA. The first application when approved will expand the Company's Phase 2 clinical trial for triple-negative breast cancer which currently is being conducted at the University of Colorado and Indiana University.
Maybe Tak Mak is persuing CFI-400945 for Entremed. He may be able to argue to the Canadians that Entremed is the best home for it because he would be able to maintain control over it, as opposed to selling it to some large cap biotech. Even though Entremed may not be able to afford a huge up front payment, they may be able to offer more in royalties and ownership. Tak is familiar with the compound, and may be the best person on earth to oversee its' developement. Even more so if it has synergistic weth 2076. He has proven that he is a great scientist, lets see if his business prowness is as spectacular. The acquisition would put Entremed back on the radar.
I totally agree. I think they're going about this the right way. Now they just need results.
Thanks for the post, Rocky...
The following statement from Ken Ren identifies the importance of the China process...
"...We are pleased with the continued execution of our integrated US-China drug development plan. Expanding our trials into China will enable us to explore the potential of ENMD-2076 at an accelerated pace due to faster patient recruitment and lower study costs, while obtaining data that will lead to advanced global drug development as well as China import drug registration..."
Two of the largest obstacles faced in conducting trials in the US is patient recruitment and cost. The former is time-consuming and slows data accumulation and analysis; and, the latter is obvious by definition.
While some may say Enmd has become the Walmart of pharmaceutical development, others will agree that this is a shrewd and, hopefully, effective way to accumulate large amounts of data quickly and cost effectively. It could reduce review time and the approval process by years...
EntreMed Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA To Expand Clinical Trial For Advanced/Metastatic Sarcoma
ROCKVILLE, Md., June 27, 2013 - EntreMed, Inc. (ENMD), a
clinical-stage pharmaceutical company developing therapeutics for the
treatment of a variety of cancers, announced today that it has
submitted a new drug global clinical trial application with the China
Food and Drug Administration (CFDA) for its proprietary oncology drug
candidate, ENMD-2076. The purpose of the application is to expand the
Company's Phase 2 clinical trial in advanced/metastatic sarcoma which
currently is being conducted at Princess Margaret Hospital. This
submission is the Company's second new drug global clinical trial
application with the CFDA. The first application when approved will
expand the Company's Phase 2 clinical trial for triple-negative breast
cancer which currently is being conducted at the University of
Colorado and Indiana University. More information about the clinical
trials can be found at www.clinicaltrials.gov.
Ken K. Ren, Ph.D., EntreMed's Chief Executive Officer, commented, "We
are advancing our global development program in sarcoma because we
believe that ENMD-2076, with its unique dual targets of Aurora A and
VEGFR, may provide therapeutic benefits to the targeted patient
population with unmet medical needs. We are excited about expanding
the trial and are encouraged by the support from our investigators.
We look forward to working with the CFDA to move our application
forward towards approval. Regarding our application for
triple-negative breast cancer, we are currently working with the
Center for Drug Evaluation of CFDA on the technical review and have
begun laying out the groundwork for the trial, which is targeted to be
launched by the fourth quarter of this year after approval is
received.
Dr. Ren continued, "We are pleased with the continued execution of
our integrated US-China drug development plan. Expanding our trials
into China will enable us to explore the potential of ENMD-2076 at an
accelerated pace due to faster patient recruitment and lower study
costs, while obtaining data that will lead to advanced global drug
development as well as China import drug registration."
"In parallel with the advancement of our ENMD-2076 program," Dr. Ren
further continued, "we are also evaluating additional drug candidates
to add to our pipeline, with emphasis on compounds that have the
potential for gaining widespread market acceptance globally or in
China and for which development can be carried out cost-effectively
under our global drug development strategy."
Small piece of news:
EntreMed files new drug global clinical trial application for ENMD-2076 with China CFDA to expand clinical trial for advanced/metastatic sarcoma
Font size: A | A | A
7:02 AM ET 6/27/13 | Briefing.com
RELATED QUOTES
4:00 PM ET 6/26/13
Symbol Last % Chg
ENMD
1.95 0.00%
Quotes delayed at least 15 minutes
The purpose of the application is to expand the Company's Phase 2 clinical trial in advanced/metastatic sarcoma which currently is being conducted at Princess Margaret Hospital. This submission is the Company's second new drug global clinical trial application with the CFDA. The first application when approved will expand the Company's Phase 2 clinical trial for triple-negative breast cancer which currently is being conducted at the University of Colorado and Indiana University
Good find, TBorg. We have a Cairn Terrier who had a mast cell tumor removed from one of her front legs last year - it took weeks for her to heal and a skin graft to cover the wound. ENMD-2076/radiation may have been a better route for her. Maybe approval for animals will be quicker than the FDA process for humans, huh?
TB,
Thank you so much. Good luck with the vet visit today. We have had S J 11 years and the vet estimated
That he was 3 when we rescued him, putting him at about 14. We have found that acupunture treatments
help his arthritis.
BW
We too are dog lovers... we lost our oldest Irish Setter last November after 12 and a half years... our youngest now has an enlarged heart and we are on our way to the vet today... these guys are so important in our lives...
We will buy SJ Goes Home on Amazon...
TB,
Interesting about the dogs. No bigger dog lover than my self and wife. She wrote a children's book, SJ Goes Home, attempting to educate children to the evils of puppy mills and the joys of pet adoption. On amazon.com
If anyone interested. It is the story of our own adopted collie.
Interesting potential use for Enmd 2076 in combo with radiation in dogs...
The radiosensitizing effect of the aurora kinase inhibitors, ENMD-2076, on canine mast cell tumours in vitro.
Shiomitsu K, Sajo E, Rubin C, Sehgal I.
SourceDepartment of Veterinary Clinical Sciences, Cancer Treatment Unit, Louisiana State University, Baton Rouge, LA, USA.
Abstract
ENMD-2076 is an aurora kinase inhibitor that also has multi-target tyrosine kinase inhibitor properties. In this study, the mRNA and the protein expression of aurora-A and aurora-B were evaluated in three canine mast cell tumour cell lines. Dose-dependent cytotoxicity was seen in the cells treated, and it affected the cell cycle with cells in the G2/M phase being selectively killed. The cells were also evaluated for radiosensitivity with/without ENMD-2076, and radiosensitization was seen after 3?Gy and 6?Gy exposures with ENMD-2076 for 48?h. Protein expression of caspase-3 was gradually increased, and the expression intensity was highest at 24?h post irradiation in cells without ENMD-2076 treatment, which indicates that radiation exposure with ENMD-2076-induced cell death faster than radiation treatment alone. Our study results suggest the potential usefulness of treating canine mast cell tumours with aurora kinase inhibitors alone or in conjunction with radiation therapy.
http://www.ncbi.nlm.nih.gov/pubmed/23763774
Hey BW
Mak is the common denominator... but, as mentioned, there are seven other inventors of the patent including the owner/applicant, the University Health Network.
There may be an opportunity for licensing for development to Entremed similar to Children Hospital for Thalidomide, Angio- and Endostatin, and 2ME2... but ENMD's product development history is less than stellar... Mak, again would be the deciding factor... The cost??? Well, it would seem that it would be astronomical if the compound is what it is purported to be...
RNA inhibition is a new field which has posed many difficulties to those attempting drug development... but, anything is possible...
Steve, as we all know, gets excited over the anectdotal and ignores the facts... and remember this is a guy who claims to have invested a million dollars in Entremed which, if true, is currently worth about $10K-$20K... Who would place that much money in such a highly speculative stock???
Again, so far this is media hype... until there is a publication and peer review, everything is questionable...
"...If I am wrong, I will be the first to admit it.."
If only!
"...If I am wrong, I will be the first to admit it.."
If only!
ummm... sounds a little reminiscent of another "cure" story published in the media about 15 years ago... this again is a pre-clinical trial in mice... there has yet to be a peer review or publication in a scientific journal... ...and the information coming out is from the popular media, not scientific journals... the use of the phrase "sharp shooter" is indicative of this...
The patent is owned by the Toronto University Health Network and their are eight inventors listed including Dr. Mak... according to Mak, it took $40M to develop which was accumulated, mostly, from donors.
There is some skepticism among some scientists because the compound is effectively an RNA inhibitor which poses many problems in development and administration...
And again, as we have painfully learned before,there is often a non-bridgeable gap between a mouse and man...
It may be that they are on to something, but there is much yet to be proven...
Celgene is very interested in CFI-400945 and will never let any other company
get their hands on it, period.
Better if EntreMed buys CFI-400945 because Celgene owns 28 % of EntreMed
Look at their other investment Bluebird which Celgene backed like EntreMed.
Celgene knows how to pick winners and have backed EntreMed for years.
Once the foundation is laid in China this company will fly with ENMD 2076, Panzem and finally CFI-400945.
You know Dr Tak Mak is a winner
And, by the way, don't forget that EntreMed has a shelf registration for its common stock totaling $30 million available to be used for... "Move ahead with EntreMed." Best wishes, Dr. Steve.
Don't you worry, rkopenec. If this new drug discovered by Dr. Tak Mak and his team of scientists is what it is claimed to be (a sharpshooting kinase inhibitor and cancer-killer), and if EntreMed wants to add this drug to its portfolio (they have already stated that they intend to purchase a new drug this calendar year), I am confident that the money will be there, what with new financing opportunities opening up widely in China due to the expansion of the EntreMed umbrella in the far east. Chinese investors have already added twenty million dollars to EntreMed's coffers over the past few years, and it would not surprise me one bit if they (or other Chinese financiers) would make new and additional investments in EntreMed in order to expand the company's efforts in combating cancer. Dr. Mak and his colleagues are the right people to have working with EntreMed to attain its goal of global pharmaceutical success. In addition to personally having invested in EntreMed to the tune of 365,000 shares in its stock, Dr. Mak brings to EntreMed's Executive Board a wealth of expertise, numerous connections in the scientific and financial community (in the USA, Canada and China), and (most of all) an overpowering passion to make a lasting contribution to anti-cancer treatment worldwide. Just watch his presentation at the Princess Margaret Hospital in Toronto recently, and you will likewise be proud and grateful to have this highly-awarded and greatly-respected cancer researcher right smack-dab in the middle of the most important cancer research in decades. Congratulations to Dr. Mak, Dr. Slamon and their colleagues for their persistence, their motivation and their efforts in helping to conquer cancer. EntreMed is exceedingly fortunate to have Dr. Mak, Dr. He, Dr. Ren and all their other colleagues involved and dedicated to EntreMed's continuing anti-cancer discovery program. "Move ahead with EntreMed." Best wishes, Dr. Steve.
Having now read the Toronto Star article, I conclude that there is no connection to Entremed. Tak Mak wears
many hats and this one just isn't ours. Still, let's wish him great success against this dreaded scourge.
Could EntreMed be preparing to purchase CFI-400945 and to combine it into a cocktail with ENMD-2076 treatment??
Where the heck are they gonna get the money to do that? They better get the share price up if they plan to dilute again....
Then, how will they fund a clinical trial?
Perhaps a partner? I think I would prefer that to dilution. Have the partner pay all trial costs for a percentage.
Followers
|
52
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
12383
|
Created
|
04/07/04
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |